PA8557501A1 - Benzamida, heteroarilamida y amidas inversas - Google Patents
Benzamida, heteroarilamida y amidas inversasInfo
- Publication number
- PA8557501A1 PA8557501A1 PA20028557501A PA8557501A PA8557501A1 PA 8557501 A1 PA8557501 A1 PA 8557501A1 PA 20028557501 A PA20028557501 A PA 20028557501A PA 8557501 A PA8557501 A PA 8557501A PA 8557501 A1 PA8557501 A1 PA 8557501A1
- Authority
- PA
- Panama
- Prior art keywords
- heteroarilamida
- benzamida
- amidas
- invested
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS INHIBIDORES DE P2X7 DE FORMULA I Y A PROCESOS PARA SU PREPARACION, A INTERMEDIOS UTILES EN SU PREPARACION, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO EN TERAPIA. LOS COMPUESTOS ACTIVOS DE LA PRESENTE INVENCION SON POTENTES INHIBIDORES DE P2X7, Y COMO TALES SON UTILES EN EL TRATAMIENTO DE LA INFLAMACION, OSTEOARTRITIS, ARTRITIS REUMATOIDE, CANCER, REPERFUSION O ISQUEMIA EN LA APOPLEJIA O INFARTO DE MIOCARDIO, ENFERMEDADES AUTOINMUNES Y OTROS TRASTORNOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33678101P | 2001-11-12 | 2001-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8557501A1 true PA8557501A1 (es) | 2003-06-30 |
Family
ID=23317638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20028557501A PA8557501A1 (es) | 2001-11-12 | 2002-10-29 | Benzamida, heteroarilamida y amidas inversas |
Country Status (34)
Country | Link |
---|---|
US (2) | US7214677B2 (es) |
EP (1) | EP1448535B1 (es) |
JP (1) | JP4365218B2 (es) |
KR (1) | KR20050043785A (es) |
CN (1) | CN1585755A (es) |
AP (1) | AP2004003028A0 (es) |
AR (1) | AR038365A1 (es) |
AT (1) | ATE502020T1 (es) |
BR (1) | BR0214044A (es) |
CA (1) | CA2466724C (es) |
CY (1) | CY1111405T1 (es) |
DE (1) | DE60239485D1 (es) |
DK (1) | DK1448535T3 (es) |
EA (1) | EA200400488A1 (es) |
EC (1) | ECSP045097A (es) |
ES (1) | ES2358988T3 (es) |
GT (1) | GT200200224A (es) |
HN (1) | HN2002000319A (es) |
HU (1) | HUP0401936A3 (es) |
IL (1) | IL161329A0 (es) |
IS (1) | IS7216A (es) |
MA (1) | MA27144A1 (es) |
MX (1) | MXPA04004465A (es) |
NO (1) | NO20041922L (es) |
OA (1) | OA12718A (es) |
PA (1) | PA8557501A1 (es) |
PE (1) | PE20030537A1 (es) |
PL (1) | PL370762A1 (es) |
PT (1) | PT1448535E (es) |
SV (1) | SV2004001393A (es) |
TN (1) | TNSN04083A1 (es) |
UY (1) | UY27535A1 (es) |
WO (1) | WO2003042191A1 (es) |
ZA (1) | ZA200402754B (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
JP2006513205A (ja) * | 2002-12-31 | 2006-04-20 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
ATE371738T1 (de) * | 2003-04-17 | 2007-09-15 | Affectis Pharmaceuticals Ag | Mittel und verfahren zur diagnose und behandlung affektiver störungen |
EP1837330B1 (en) * | 2003-05-12 | 2012-10-24 | Pfizer Products Inc. | Benzamide inhibitors of the P2X7 receptor |
JP4731468B2 (ja) | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
US20070032465A1 (en) * | 2003-05-29 | 2007-02-08 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
CN100525526C (zh) * | 2003-07-11 | 2009-08-05 | 汤姆森许可贸易公司 | 通用移动电话系统网络的覆盖微小区结构 |
WO2005019182A1 (en) * | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists |
SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
US7598412B2 (en) * | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ITMI20040255A1 (it) * | 2004-02-17 | 2004-05-17 | Univ Degli Studi Milano | Sostanze ad attivita' antiangiogenica |
AU2005258911A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
AU2005258924A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
JP2008504363A (ja) * | 2004-06-29 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | P2x7受容体のベンズアミド阻害剤を利用する併用療法 |
WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
KR20080002790A (ko) * | 2005-03-29 | 2008-01-04 | 코와 가부시키가이샤 | 관절 류머티즘의 예방 및/또는 치료약 |
EP1906960A4 (en) * | 2005-07-11 | 2010-03-10 | Astrazeneca Ab | NEW COMBINATION 1 |
WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
DK2404919T3 (da) | 2005-11-08 | 2013-11-04 | Vertex Pharma | Heterocyclisk forbindelse, der er egnet som modulator af ATP-bindende kassettetransportører |
US20070117497A1 (en) * | 2005-11-22 | 2007-05-24 | Cabot Microelectronics Corporation | Friction reducing aid for CMP |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2038264B1 (en) * | 2006-06-29 | 2016-10-26 | F.Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
US8828966B2 (en) * | 2006-10-03 | 2014-09-09 | Claire Mitchell | Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors |
DE102006049618A1 (de) * | 2006-10-20 | 2008-05-08 | Tschesche, Harald, Prof. Dr. | Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
AU2008271051C1 (en) | 2007-06-29 | 2012-10-04 | Acucela Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
CA2691507C (en) * | 2007-07-19 | 2016-06-21 | H. Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
RU2541430C2 (ru) | 2007-10-05 | 2015-02-10 | Акусела Инк. | Композиции и способы лечения нейродегенеративных заболеваний |
JP2011500767A (ja) | 2007-10-26 | 2011-01-06 | グラクソ グループ リミテッド | P2x7モジュレータとしての4−ベンゾイル−1−置換ピペラジン−2−オン誘導体 |
JP5592265B2 (ja) | 2007-11-01 | 2014-09-17 | アキュセラ インコーポレイテッド | 眼の疾患及び障害治療用のアミン誘導体化合物 |
BRPI0821039B8 (pt) | 2007-12-07 | 2021-05-25 | Vertex Pharma | formas sólidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico, processo de preparação das mesmas, composições farmacêuticas compreendendo as mesmas e usos |
MX2010006183A (es) | 2007-12-07 | 2010-10-15 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
GB0724625D0 (en) * | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
NZ587799A (en) | 2008-03-25 | 2012-06-29 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
GB2463151A (en) * | 2008-09-05 | 2010-03-10 | Acucela Inc | Amine derivative compounds for treating ophthalmic diseases and disorders |
US8674137B2 (en) * | 2008-10-22 | 2014-03-18 | Acucela Inc. | Compounds for treating ophthalmic diseases and disorders |
ES2380908T3 (es) | 2009-04-14 | 2012-05-21 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su uso |
JP5860398B2 (ja) | 2009-07-02 | 2016-02-16 | アキュセラ インコーポレイテッド | 視覚サイクルモジュレーターの薬理 |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
MX2012007929A (es) | 2010-01-07 | 2012-11-21 | Selexagen Therapeutics Inc | Inhibidores erizo. |
WO2011085261A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
WO2011109833A2 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
EP2569281A1 (en) | 2010-05-14 | 2013-03-20 | Affectis Pharmaceuticals AG | Novel methods for the preparation of p2x7r antagonists |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
JP2014513671A (ja) | 2011-02-22 | 2014-06-05 | アクテリオン ファーマシューティカルズ リミテッド | P2x7受容体アンタゴニストとしてのベンズアミド誘導体 |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
TW201309706A (zh) | 2011-07-22 | 2013-03-01 | Actelion Pharmaceuticals Ltd | 作為p2x7受體拮抗劑之雜環醯胺衍生物 |
US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
AU2013210682B2 (en) | 2012-01-20 | 2017-05-25 | Idorsia Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
EP2935211B1 (en) | 2012-12-18 | 2016-11-09 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
CA2896790C (en) | 2013-01-22 | 2022-05-10 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
ES2728531T3 (es) | 2013-07-08 | 2019-10-25 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con C-N como agentes para combatir parásitos |
CN105848657B (zh) | 2013-11-12 | 2020-05-22 | 沃泰克斯药物股份有限公司 | 制备用于治疗cftr介导的疾病的药物组合物的方法 |
JP6422164B2 (ja) * | 2013-12-26 | 2018-11-14 | 塩野義製薬株式会社 | 含窒素6員環誘導体およびそれらを含有する医薬組成物 |
HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
RU2753524C2 (ru) | 2016-10-17 | 2021-08-17 | Сионоги Энд Ко., Лтд. | Бициклические азотсодержащие гетероциклические производные и включающие их фармацевтические композиции |
CN106674098B (zh) * | 2016-12-23 | 2019-07-02 | 中国医科大学 | N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US146200A (en) * | 1874-01-06 | Improvement in wind-wheels | ||
US144170A (en) * | 1873-10-28 | Improvement in scarf-clasps | ||
US71509A (en) * | 1867-11-26 | mcclellan | ||
US144213A (en) * | 1873-11-04 | Improvement in faucets | ||
US158883A (en) * | 1875-01-19 | Improvement in wax-thread sewing-machines | ||
US128498A (en) * | 1872-07-02 | Improvement in tile-molds | ||
US77018A (en) * | 1868-04-21 | Improvement in dove-tail mabkers | ||
US74576A (en) * | 1868-02-18 | Adam myers | ||
US123378A (en) * | 1872-02-06 | Improvement in time-locks | ||
US71529A (en) * | 1867-11-26 | John e | ||
US142194A (en) * | 1873-08-26 | William w | ||
AU542544B2 (en) * | 1980-03-12 | 1985-02-28 | Nippon Kayaku Kabushiki Kaisha | Tetrahydrophthalimide derivatives |
EP0077938A3 (en) * | 1981-10-23 | 1983-08-24 | Mitsubishi Kasei Corporation | N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition |
EP0185731A4 (en) * | 1984-06-12 | 1988-11-02 | Fmc Corp | WEED-KILLING 2-ARYL-1,2,4-TRIAZINE-3,5 (2H, 4H) -DIONE AND THEIR SULFUR ANALOGS. |
US4766233A (en) * | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
AU2328188A (en) * | 1987-09-23 | 1989-04-18 | Ciba-Geigy Ag | Heterocyclic compounds |
US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
JP3089621B2 (ja) * | 1990-12-17 | 2000-09-18 | 日産化学工業株式会社 | ウラシル誘導体 |
KR930703259A (ko) | 1990-12-17 | 1993-11-29 | 알베르투스 빌헬무스 요아네스 쩨스트라텐 | 살균성 이소퀴놀린 유도체 |
GB9110679D0 (en) * | 1991-05-17 | 1991-07-10 | Sandoz Ltd | Improvements in or relating to organic compounds |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
DE4405614A1 (de) * | 1994-02-22 | 1995-08-24 | Bayer Ag | Substituierte Triazolinone |
US5686061A (en) | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
GB9412603D0 (en) * | 1994-06-23 | 1994-08-10 | Sandoz Ltd | Organic compounds |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
ATE267011T1 (de) | 1995-12-21 | 2004-06-15 | Bristol Myers Squibb Pharma Co | Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren |
DE69706407T2 (de) * | 1996-03-29 | 2002-05-29 | Searle & Co | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
DE19701287A1 (de) * | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben |
AU6753298A (en) | 1997-03-25 | 1998-10-20 | Astra Pharmaceuticals Limited | Novel pyridine derivatives and pharmaceutical compositions containing them |
WO1998043973A1 (de) | 1997-03-27 | 1998-10-08 | Novartis Ag | Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
SE9704272D0 (sv) * | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
JPH11318492A (ja) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | 蛍光発生性基質を含有する組成物 |
US6320078B1 (en) | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
ES2249059T3 (es) | 1998-12-16 | 2006-03-16 | Bayer Healthcare Ag | Nuevos compuestos de bifenilo y analogos de bifenilo como antagonista de integrina. |
KR100710091B1 (ko) * | 1999-04-09 | 2007-04-25 | 아스트라제네카 아베 | 아다만탄 유도체 |
JP2003500387A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Xa因子の阻害剤 |
SE9901875D0 (sv) * | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
EP1088821A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
MXPA02005102A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Retro-anandamidas, ligandos de receptor de canabinoide de alta afinidad y estabilidad. |
SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10005284A1 (de) | 2000-02-07 | 2001-08-09 | Bayer Ag | Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen |
PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
JP4731468B2 (ja) * | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
JP2008504363A (ja) * | 2004-06-29 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | P2x7受容体のベンズアミド阻害剤を利用する併用療法 |
AU2005258911A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
AU2005258924A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
-
2002
- 2002-10-29 PA PA20028557501A patent/PA8557501A1/es unknown
- 2002-10-30 GT GT200200224A patent/GT200200224A/es unknown
- 2002-11-04 MX MXPA04004465A patent/MXPA04004465A/es active IP Right Grant
- 2002-11-04 ES ES02783358T patent/ES2358988T3/es not_active Expired - Lifetime
- 2002-11-04 DK DK02783358.1T patent/DK1448535T3/da active
- 2002-11-04 IL IL16132902A patent/IL161329A0/xx unknown
- 2002-11-04 WO PCT/IB2002/004613 patent/WO2003042191A1/en active Application Filing
- 2002-11-04 PT PT02783358T patent/PT1448535E/pt unknown
- 2002-11-04 AP APAP/P/2004/003028A patent/AP2004003028A0/en unknown
- 2002-11-04 KR KR1020047007124A patent/KR20050043785A/ko not_active Application Discontinuation
- 2002-11-04 HU HU0401936A patent/HUP0401936A3/hu unknown
- 2002-11-04 BR BR0214044-6A patent/BR0214044A/pt not_active IP Right Cessation
- 2002-11-04 DE DE60239485T patent/DE60239485D1/de not_active Expired - Lifetime
- 2002-11-04 EA EA200400488A patent/EA200400488A1/ru unknown
- 2002-11-04 OA OA1200400127A patent/OA12718A/en unknown
- 2002-11-04 PL PL02370762A patent/PL370762A1/xx not_active Application Discontinuation
- 2002-11-04 AT AT02783358T patent/ATE502020T1/de active
- 2002-11-04 JP JP2003544027A patent/JP4365218B2/ja not_active Expired - Fee Related
- 2002-11-04 CA CA002466724A patent/CA2466724C/en not_active Expired - Fee Related
- 2002-11-04 CN CNA028224752A patent/CN1585755A/zh active Pending
- 2002-11-04 EP EP02783358A patent/EP1448535B1/en not_active Expired - Lifetime
- 2002-11-05 PE PE2002001077A patent/PE20030537A1/es not_active Application Discontinuation
- 2002-11-08 UY UY27535A patent/UY27535A1/es not_active Application Discontinuation
- 2002-11-11 AR ARP020104318A patent/AR038365A1/es unknown
- 2002-11-11 SV SV2002001393A patent/SV2004001393A/es not_active Application Discontinuation
- 2002-11-11 HN HN2002000319A patent/HN2002000319A/es unknown
- 2002-11-12 US US10/292,887 patent/US7214677B2/en not_active Expired - Fee Related
-
2004
- 2004-04-07 IS IS7216A patent/IS7216A/is unknown
- 2004-04-08 ZA ZA200402754A patent/ZA200402754B/en unknown
- 2004-04-28 MA MA27660A patent/MA27144A1/fr unknown
- 2004-05-06 EC EC2004005097A patent/ECSP045097A/es unknown
- 2004-05-11 NO NO20041922A patent/NO20041922L/no not_active Application Discontinuation
- 2004-05-11 TN TNP2004000083A patent/TNSN04083A1/fr unknown
-
2005
- 2005-10-18 US US11/253,112 patent/US7235549B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 CY CY20111100413T patent/CY1111405T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8557501A1 (es) | Benzamida, heteroarilamida y amidas inversas | |
UY27740A1 (es) | Nuevos compuestos | |
SV2010003497A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
HN2003000039A (es) | 2-(PIRIMIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS | |
DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
GT200900027A (es) | Compuestos organicos | |
UY30748A1 (es) | Compuesto0s novedosos | |
DOP2010000387A (es) | Compuestos pirazolicos 436 | |
PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
PA8583401A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
PA8577101A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
SV2009002832A (es) | 1h imidazopiridinas sustituidas con hidroxi y procedimientos | |
UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
ECSP099706A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor | |
HN2003000182A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodo para su uso | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
GT200600117A (es) | Nuevos compuestos farmaceuticos | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
UY30808A1 (es) | Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones | |
UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. |